Author

Fen Liu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

FXR1 Promotes Esophageal Squamous Cell Carcinoma via JAK2/STAT3/B7-H3 Pathway

Background/Aim: Esophageal squamous cell carcinoma (ESCC) is aggressive and has a poor prognosis. RNA-binding protein FXR1 contributes to tumor progression, but its role and mechanism in ESCC remain largely unclear. This study aimed to explore the expression, prognostic value, and molecular mechanism of FXR1 in ESCC. M...

Xiao-Li Wang, Qian-Wen Miao, Xiao-Yuan Liu et al. · Anticancer Research · 0 citations

Open access Sep 2026

Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials

Antibody-drug conjugates (ADCs) have become the standard treatment for HER2-positive(HER2+)advanced breast cancer following the failure of trastuzumab or taxane. Nevertheless, there are no direct head-to-head trials comparing different ADCs. We searched PubMed, Embase, the Cochrane Library and abstracts from...

Fen Liu, Yong Pan, Jin-Lan Li et al. · Frontiers in Pharmacology · 0 citations

Open access Sep 2026

Low-dose taxanes induce γδ-T cell reprogramming and ANXA6/PPP2R1A release to synergistically treat triple-negative breast cancer

Taxanes play pivotal roles across therapeutic stages of triple-negative breast cancer (TNBC), yet their efficacy is substantially limited by drug resistance and systemic toxicity. Immunotherapy has been found to enhance the efficacy of chemotherapy. Here, we investigated the synergistic antitumor activity between tax...

Rong Ma, Ying Zhou, Tian-Tian Yu et al. · Cell Death & Disease · 0 citations